LDT Regulation: The Plot Thickens

There have been some interesting developments over the last few weeks in the ongoing discussion about FDA’s desire to regulate LDTs. Pathologists Still Oppose Regulation At the annual meeting Nov. 12-14 of the Association for Molecular Pathology (AMP) a special...

NY-ESO-1, An Emerging Biomarker for Ovarian Cancer

In a previous post I questioned whether ovarian cancer is being under-served by personalized medicine, and promised to dig a bit deeper into some of the advancements that ARE being made for this disease. The first pass has been to look at targeted therapeutics, and...